OVULEN-28
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OVULEN-28 (OVULEN-28).
Combination estrogen-progestin oral contraceptive that inhibits ovulation primarily by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, and altering cervical mucus and endometrial lining.
| Metabolism | Ethinyl estradiol is primarily metabolized via CYP3A4; ethynodiol diacetate undergoes extensive first-pass metabolism, converted to norethindrone and other metabolites. |
| Excretion | Renal: ~50% as metabolites; Fecal/biliary: ~40% as conjugated metabolites; <1% unchanged in urine. |
| Half-life | Ethinyl estradiol: 13-27 hours (mean ~17 hours); Norethindrone: 5-14 hours (mean ~8 hours). Clinical context: Steady state reached within 5-7 days. |
| Protein binding | Ethinyl estradiol: 98-99% bound (albumin, SHBG); Norethindrone: 80-85% bound (albumin, SHBG). |
| Volume of Distribution | Ethinyl estradiol: 2.3-3.2 L/kg (extensive tissue distribution); Norethindrone: 2.1-2.8 L/kg (distribution consistent with steroid hormones). |
| Bioavailability | Ethinyl estradiol: 38-48% (extensive first-pass metabolism); Norethindrone: 50-77% (oral bioavailability). |
| Onset of Action | Oral: Contraceptive effect begins after 7 days of continuous dosing. Ovulation suppression occurs within the first cycle. Maximal hormone levels achieved 1-2 hours post-dose. |
| Duration of Action | Contraceptive protection persists for 24 hours with daily dosing. Withdrawal bleeding typically occurs 2-3 days after last active tablet. Hormonal effects decline over 5-7 days after discontinuation. |
One tablet (ethinyl estradiol 0.05 mg / ethynodiol diacetate 1 mg) orally once daily for 21 days followed by 7 days placebo; continuous cycle.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; use with caution in severe renal impairment. |
| Liver impairment | Contraindicated in acute or chronic liver disease, including hepatic adenomas or carcinoma; discontinue if jaundice develops. |
| Pediatric use | Not indicated for use before menarche; postmenarche: same as adult dosing after assessment of bone age and growth potential. |
| Geriatric use | Not indicated for use after menopause; no specific dose adjustment, but consider increased risk of thromboembolic events and estrogen-dependent neoplasms. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OVULEN-28 (OVULEN-28).
| Breastfeeding | Excreted in breast milk in low amounts; M/P ratio ~0.3. No adverse effects reported in breastfed infants. Use with caution only if necessary. |
| Teratogenic Risk | First trimester exposure is associated with increased risk of noncardiac birth defects (e.g., limb reduction defects) and cardiac anomalies (e.g., VSD, TGA). Postnatal studies show no increased risk with second or third trimester use. Avoid use in pregnancy due to known risks. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day), particularly in women over 35.
| Serious Effects |
Thrombophlebitis or thromboembolic disorders; history of deep-vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or carcinoma; active liver disease; hypersensitivity to any component.
| Precautions | Increased risk of thrombotic disorders (e.g., venous thromboembolism, arterial thromboembolism), cardiovascular events, hepatic neoplasia, and gallbladder disease. Discontinue if jaundice or visual disturbances occur. Monitor for hypertension, depression, and fluid retention. |
Loading safety data…
| Monitor blood pressure, glucose, and liver function. If pregnancy occurs, discontinue immediately and perform ultrasound for fetal anatomy. |
| Fertility Effects | Suppresses ovulation by inhibiting gonadotropins. Normal fertility returns upon discontinuation. No known long-term impairment. |